As shown in Fig. 7e, 6-AN treatment could not inhibit PHLDA3 knockout xenograft tumor growth in vivo (Fig. 7e, upper panels; Supplementary Fig. 7B), most likely due to the constitutively activated AKT pathway (Fig. 7e, lower panel). Here, PHLDA3 is linked to neoplasm.